IPHA

Innate Pharma

9 hedge funds and large institutions have $735K invested in Innate Pharma in 2023 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 0 increasing their positions, 4 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
9
Holders Change
Holders Change %
0%
% of All Funds
0.14%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
3
Increased
Reduced
4
Closed
3
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Shares
Change %
Optiver Holding
1
Optiver Holding
Netherlands
$257K -$447K -142,301 -63%
Millennium Management
2
Millennium Management
New York
$155K -$39.1K -12,449 -20%
Morgan Stanley
3
Morgan Stanley
New York
$145K -$5.14K -1,673 -3%
ETC
4
Exchange Traded Concepts
Oklahoma
$133K +$133K +42,431 New
Citadel Advisors
5
Citadel Advisors
Florida
$41.7K +$41.7K +13,281 New
SPIA
6
Steward Partners Investment Advisory
New York
$1.54K
Barclays
7
Barclays
United Kingdom
$1K
RhumbLine Advisers
8
RhumbLine Advisers
Massachusetts
$643 +$643 +205 New
UBS Group
9
UBS Group
Switzerland
$449 -$3.42K -1,113 -88%
Bank of America
10
Bank of America
North Carolina
-$133K -46,749 Closed
Susquehanna International Group
11
Susquehanna International Group
Pennsylvania
-$37.8K -13,315 Closed